-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WjdamtA+8u8n0xHFpOx7HK//2ugcc9Co89UUvYOZrW0jGLwWTKJMBXnzbg6KlTKO tDHZ8s/xxeAVFL8yE4AqJQ== 0001104659-07-089919.txt : 20071219 0001104659-07-089919.hdr.sgml : 20071219 20071219170756 ACCESSION NUMBER: 0001104659-07-089919 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070702 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20071219 DATE AS OF CHANGE: 20071219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-32715 FILM NUMBER: 071316948 BUSINESS ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 1-781-398-0700 MAIL ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 8-K/A 1 a07-31665_18ka.htm 8-K/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K/A

 

Amendment No. 1 to Form 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported) July 2, 2007

 

Interleukin Genetics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-32715

 

94-3123681

(Commission File Number)

 

(IRS Employer Identification No.)

 

135 Beaver Street Waltham, MA

 

02452

(Address of Principal Executive Offices)

 

(Zip Code)

 

(781) 398-0700

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Explanatory Note

 

As previously reported in a Current Report on Form 8-K filed on July 5, 2007 (the “Initial Filing”), the Board of Directors of Interleukin Genetics, Inc. (the “Company”) appointed its then-Chairman, Thomas R. Curran, Jr., age 48, as Interim Chief Executive Officer of the Company on July 2, 2007. This Amendment No. 1 amends the Initial Filing to include the terms of the compensation arrangement for Mr. Curran’s services between the Company and Mr. Curran’s employer, Alticor Inc. (“Alticor”), the corporate parent of Pyxis Innovations Inc., the Company’s largest stockholder.

 

ITEM 1.01.            ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

 

The disclosure provided under Item 5.02 below is incorporated herein by reference.

 

 

ITEM 5.02.            DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

 

On December 17, 2007, the Company entered into an agreement with Alticor, effective as of July 3, 2007, with respect to the services of Mr. Curran.  Pursuant to the terms of the agreement, and in exchange for Mr. Curran’s services as Interim Chief Executive Officer to the Company during the term of the agreement, the Company will pay directly to Alticor $30,000 per month.  The Company will reimburse Mr. Curran directly for travel and other incidental expenses incurred in the performance of his services for the Company. Either the Company or Alticor may terminate the agreement at any time by providing fifteen days advance written notice to the other party.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Interleukin Genetics, Inc.

 

 

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

 

Date: December 19, 2007

 

/s/ THOMAS R. CURRAN, JR.

 

 

 

Thomas R. Curran, Jr.

 

 

 

Interim Chief Executive Officer

 

 

 

(Signature)

 

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----